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control groups (placebo, Nitroglycerin or Dobutamine plus conventional treatment).
The comprehensive evaluation of relative risk for 30- (RR 1.004, 95% CI 0.995-
1.014) and 180-day (RR 1.006, 95% CI 0.988-1.024) mortality showed no signiﬁcant
differences between two groups. There was no signiﬁcant difference in the mortality
rate between the group of less than 30-day (RR 1.015, 95% CI 0.989-1.041) and the
group of 90-day (RR 1.011, 95% CI 0.974-1.048). Moreover, there was also no
signiﬁcant difference found between the 30- (RR 1.011, 95% CI 0.998-1.024) and 90-
day readmission rate (RR 1.049, 95% CI 0.963-1.144). In the meantime, cumulative
meta-analysis demonstrated no statistically signiﬁcant beneﬁts on improving the
mortality rate with Nesiritide administration in ADHF.
Conclusions: Neither mortality nor readmission to the hospital was reduced or
increased for any length of follow-up after treatment with Nesiritide in addition to
conventional treatment in adult patients with ADHF. Further investigation on the
mortality beneﬁt of Nesiritide treatment in patients with ADHF is unlikely to yield a
positive result. Although Nesiritide could reduce dyspnea to some extent if added to
conventional treatment, strict attention should be paid on the pharmaceutical indica-
tion for patient with ADHF.
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Objectives: The effects of Ginkgo biloba extract (GBE) in combination with anti-
platelet drugs on platelet aggregation were not clear. The objective of this meta-
analysis is to elucidate the effects of GBE in combination with anti-platelet drugs on
platelet aggregation and bleeding time in order to provide reference proof for rational
use of them.
Methods: Randomized controlled trails (RCTs) were searched from PubMed, Spring
Ling, Biosis Previews and The Cochrane without restriction of year and language.
RCTs involving the combination of GBE with anti-platelet drugs and assessing the
effects of the combination on platelet aggregation or bleeding time were included.
Collagen-induced platelet aggregation, ADP-induced platelet aggregation and
bleeding time were used as analysis indexes. A meta-analysis was performed by
RevMan 5.0.
Results: Six RCTs with 316 participants were included in the meta-analysis. The
combination of GBE with anti-platelet drugs has inhibitory trend on ADP-induced
platelet aggregation [MD¼-3.45, 95% CI (-7.39, 0.50), P¼0.09], and no inhibitory
effect on collagen-induced platelet aggregation [MD¼-0.56, 95% CI (-3.91, 2.80),
P¼0.74]. No difference of prolonged bleeding time between the combination and anti-
platelet drugs used alone was noted [MD¼0.39, 95% CI (-0.09, 0.86), P¼0.11].
Conclusions: The meta-analysis suggested that compared with anti-platelet drugs
used alone, the combination of GBE with anti-platelet drugs here may not be sig-
niﬁcant inhibition on platelet aggregation, but in view to fewer studies included, the
conclusion is prudent to be applied to clinical practice and need. Larger scale
multicenter randomized controlled trial to validate in the future.
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Objectives: Elevated serum inﬂammatory markers, such as high sensitivity C-reactive
protein (hs-CRP), were regarded as risk factors for cardiovascular events. Sodium
tanshinone IIA sulfate (STS), an extract of the root of Salvia miltiorrhiza, has been
proved to have anti-inﬂammatory effects in basic researches, but the evidence sup-
porting such efﬁcacy in Coronary Heart Disease (CHD) patients remains unclear. The
purpose of this study was to access the effects of STS on elevated serum hs-CRP and
other inﬂammatory markers in patients with CHD.
Methods: This is a prospective randomized open-label blinded end point (PROBE)
designed trial. The study protocol has been approved by Ethics Committee of Xiyuan
Hospital, China Academy of Chinese Medical Sciences (2012XL022-2). 72 conﬁrmed
CHD inpatient of unstable angina (UA) or acute non-ST segment elevation myocardial
infarction (NSTEMI) with elevated serum hs-CRP were enrolled and randomized 1:1
into the control or experimental group. The control group received standard medi-
cation for treatment of CHD including 20mg atorvastatin while the experimental
group additionlly received intravenously a daily 80mg dose of STS for 14 days. The
primary outcome was serum Hs-CRP level. The secondary outcomes were other
serum imﬂammatory factors and improvement in symptoms of angina as well as side
effects. Outcome parameters were assessed blindly to treatment allocation at baseline,
immediately after the 14-day treatment period and at 30 days after the treatment
stopped.
Results: After 14-day treatment, the level of hs-CRP were signiﬁcantly reduced
(6.363.42 mg/l to 2.835.94 mg/l and 5.752.39 mg/l to 1.024.31 mg/l) in both
the experimental and control groups; The reduction of the experiment group was moreC206 JACC Vol 64/16/Suppl C j October 16–1signiﬁcant than that of the control group (P¼0.0485, IQR: 2.9(1.3, 6.05) vs 1.54
(-1.45, 3.51) mg/dL), so as the pecent change (P¼0.0114, media: 71.75% vs 30%).
The reduction in monocyte chemotactic protein 1 (MCP-1) and soluble CD40 ligand
(sCD40L) of the experiment group was more signiﬁcant than that of the control group
(P¼0.013 and P¼0.0454, respectively). At 30 days after the treatment stopped, the
level of MCP-1 had greater reduction in the experiment group compared with that of
the control group (P¼0.0253, 54.6447.38 vs 30.7239.82 pg/dL). Other inﬂam-
matory markers had no signiﬁcant reduction between groups. In addition, STS also
signiﬁcantly improved angina symptom at the two time-points after treatment. There
were no serious adverse events occurred.
Conclusions: On the background of statin therapy, a daily 80mg dose of STS intra-
venously for 14 days further reduced levels of circulating inﬂammatory markers of hs-
CRP, sCD40L and MCP-1 in UA/NSTEMI patients. Together, our study suggested
that STS could be used as a complementary treatment in CHD patients with enhanced
inﬂammatory reaction.
(Clinical Trial Registration number: ChiCTR-TRC-12002361).
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Objectives: Resistin is a novel adipokine that is involved in inﬂammatory conditions
and atherosclerosis. In this study we aimed to investigate the beneﬁcial effect of
Qishen Capsule on serum resistin levels in unstable angina.
Methods: 154 unstable angina patients were randomly assigned to two groups. One
group (regular group) received oral aspirin, clopidogrel, beta-blockers, and heparin;
the other group (combined group) received regular treatment and Qishen Capsule
(three pills, third per day). Study drugs were administered for six weeks in both
groups. Resistin levels were measured using ELISA at the beginning of the study and
at study end. Patients were evaluated monthly for blood pressure, fasting serum
glucose levels and adverse events.
Results: Both therapeutic regimens reduced resistin levels; combined treatment group
resulted in a greater decrease in resistin levels (4.171.52 ng/mL to 2.050.92 ng/
mL) when compared with regular treatment group (3.951.46 ng/mL to 2.390.91
ng/mL) (P<0.05). None of the patients experienced adverse events.
Conclusions: Results showed that combined treatment group resulted in a greater
reduction in resistin levels than regular treatment group alone.
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Objectives: To nvestigate whether it is the same by application of rosuvastatin 20mg
as atorvastatin 40mg on effectiveness and safety in patients with acute myocardial
infarction (AMI).
Methods: A total of 130 AMI patients enrolled in the study, all patients underwent
standardized treatment as guidelines recommend. After admission they were seperated
into two groups: atorvastatin 40mg/day group and and rosuvastatin 20mg/day group,
and wiould continue to take the medicine for 30 days. The primary end point was the
reduction of serum LDL-c levels, all-cause mortality, re-AMI, readmission rate within
30 days. Secondary endpoint were serum transaminases, bilirubin, serum creatinine,
urine protein.
Results: There was no signiﬁcant difference between the two groups (0.321.36,
0.401.13, P¼0.737) about the reduction of serum LDL-c levels and primary clinical
endpoint of all-cause mortality (P¼0.699), the incidence of re-AMI, readmission rate
within 30 days was lower in rosuvastatin group than in atorvastatin group (P¼0.005,
0.018, respectively). There is no no signiﬁcant difference on alanine aminotransferase
and total bilirubin between the two groups. However, the urinary protein levels
increased more in rosuvastatin group than in atorvastatin group (0.100.03 vs
0.170.05, P¼0.009), while serum creatinine levels had the same trend (80.329.6 vs
101.766.9, P¼0.030). After multivariate analysis, it is not statin used but BNP
levels, which was independent risk factors affect the prognosis.
Conclusions: Compared with atorvastatin 40mg/day, rosuvastatin 20mg/day can
reduced re-AMI, readmission rate within 30 days. However, it increased urinary
protein levels and elevated serum creatinine levels. So overall all-cause death,
myocardial infarction again, readmission rates did not differ between the two groups.
GW25-e3396
Analysis of Anticoagulation Therapy in Very Elderly Patients with Nonvalvular
Atrial Fibrillation
Zhao Sen, Qin Ming-Zhao
Tong Ren Hospital
Objectives: To investigate the current status of thromboembolism risk and antith-
rombotic treatment in very elderly patients(age80) with nonvalvular atrial9, 2014 j GW-ICC Abstracts/Cardiovascular Disease Clinical Research
